

This is a published notice on the Find a Tender service: <https://www.find-tender.service.gov.uk/Notice/024651-2022>

Planning

## High Content Screening System

MEDICINES DISCOVERY CATAPULT SERVICES LIMITED

F01: Prior information notice

Reducing time limits for receipt of tenders

Notice identifier: 2022/S 000-024651

Procurement identifier (OCID): ocds-h6vhtk-03655c

Published 2 September 2022, 1:52pm

### Section I: Contracting authority

#### I.1) Name and addresses

MEDICINES DISCOVERY CATAPULT SERVICES LIMITED

Block 35g Mereside, Alderley Park

MACCLESFIELD

SK104TG

#### Contact

James Tomlinson

#### Email

[procurement@md.catapult.org.uk](mailto:procurement@md.catapult.org.uk)

#### Country

United Kingdom

#### Region code

UKD62 - Cheshire East

**Companies House**

09928547

**Internet address(es)**

Main address

<https://md.catapult.org.uk/>

**I.3) Communication**

Additional information can be obtained from the above-mentioned address

Tenders or requests to participate must be submitted to the above-mentioned address

**I.4) Type of the contracting authority**

Other type

Research - Drug Discovery / Health

**I.5) Main activity**

Other activity

Research - Drug Discovery / Health

---

**Section II: Object**

**II.1) Scope of the procurement**

**II.1.1) Title**

High Content Screening System

**II.1.2) Main CPV code**

- 38000000 - Laboratory, optical and precision equipments (excl. glasses)

**II.1.3) Type of contract**

## Supplies

### II.1.4) Short description

The Advanced Technologies team at the Medicines Discovery Catapult (MDC) is looking to expand its current advanced microscopy facility to support both our own growing needs and provide the UK SME community access to advanced molecular and cellular imaging.

MDC is aiming purchase a confocal High Content Screening (HCS) instrument based on an automated well-plate inverted microscope, together with confocal and widefield functionalities. It is crucial for the HCS system to be flexible and provide fast and high-resolution imaging of a wide range of experiments.

The instrument should be configured to enable the use of different sample formats (2D and 3D cell models, tissue sections, fixed and live-cell) and experimental types (drug dose responses, live-cell kinetic studies, phenotypic screening, RNA scope), using a large variety of well-plate formats and a wide range of fluorophores. In addition, the HCS instrument must be supplied with a high-end solution for high content image analysis, visualization and handling.

MDC will be publishing an RFI regarding the High Content Screening (HCS) instrument during the week commencing 05/09/2022, if you wish to be involved please email [procurement@md.catapult.org.uk](mailto:procurement@md.catapult.org.uk) referencing this PIN.

This prior information notice (PIN) is a signal of future intentions to the marketplace regarding the procurement of equipment for the confocal High Content Screening (HCS) instrument. This PIN is not a call for competition. By publishing this PIN, MDC may avail itself of the opportunity to reduce the submission period from 30 days (with electronic submission) to 15 days (if the PIN has been published for at least 35 days and no longer than 12 months).

### II.1.6) Information about lots

This contract is divided into lots: No

## II.2) Description

### II.2.3) Place of performance

NUTS codes

- UKD62 - Cheshire East

### II.2.4) Description of the procurement

The Advanced Technologies team at the Medicines Discovery Catapult (MDC) is looking to expand its current advanced microscopy facility to support both our own growing needs and provide the UK SME community access to advanced molecular and cellular imaging.

MDC is aiming purchase a confocal High Content Screening (HCS) instrument based on an automated well-plate inverted microscope, together with confocal and widefield functionalities. It is crucial for the HCS system to be flexible and provide fast and high-resolution imaging of a wide range of experiments.

The instrument should be configured to enable the use of different sample formats (2D and 3D cell models, tissue sections, fixed and live-cell) and experimental types (drug dose responses, live-cell kinetic studies, phenotypic screening, RNA scope), using a large variety of well-plate formats and a wide range of fluorophores. In addition, the HCS instrument must be supplied with a high-end solution for high content image analysis, visualization and handling.

MDC will be publishing an RFI regarding the High Content Screening (HCS) instrument during the week commencing 05/09/2022, if you wish to be involved please email [procurement@md.catapult.org.uk](mailto:procurement@md.catapult.org.uk) referencing this PIN.

This prior information notice (PIN) is a signal of future intentions to the marketplace regarding the procurement of equipment for the confocal High Content Screening (HCS) instrument. This PIN is not a call for competition. By publishing this PIN, MDC may avail itself of the opportunity to reduce the submission period from 30 days (with electronic submission) to 15 days (if the PIN has been published for at least 35 days and no longer than 12 months).

### **II.3) Estimated date of publication of contract notice**

1 October 2022

---

## **Section IV. Procedure**

### **IV.1) Description**

#### **IV.1.8) Information about the Government Procurement Agreement (GPA)**

The procurement is covered by the Government Procurement Agreement: Yes

---

## **Section VI. Complementary information**

### **VI.4) Procedures for review**

#### **VI.4.1) Review body**

Medicines Discovery Catapult

Medicines Discovery Catapult Block 35, Mereside Alderley Park, Cheshire

SK10 4TG

Country

United Kingdom